Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × tazarotene × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2 Other solid neoplasm 1

Conditions

Interventions

Cisplatin 39 Pemetrexed 29 Carboplatin 23 Nivolumab 19 Gemcitabine 18 pembrolizumab 16 atezolizumab 13 Ipilimumab 10 Injections 10 Docetaxel 10 Cyclophosphamide 10 Bevacizumab 10 Radiotherapy 9 Oxaliplatin 9 Etoposide 9 tislelizumab 8 durvalumab 8 Specimen Handling 8 Paclitaxel 8 Filgrastim 8 Capecitabine 8 tremelimumab 7 lenvatinib 7 olaparib 6 niraparib 6 Vinorelbine 6 Vincristine 6 Immune Checkpoint Inhibitors 6 Biopsy 6 toripalimab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04071756 2024-02-07

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

Dana-Farber Cancer Institute

Phase 2 Terminated

8 enrolled 12 charts

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡